Payment overview · 2025
General Payments
$87.35
6 reported records · 4 companies
Healthcare provider profile · identity verified
Christopher E Lansdown, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LUCEDALE, MS · NPI 1043420383
Verified facts
What the public records show
CMS Open Payments records show Christopher E Lansdown, M.D. received $87.35 in general payments during 2025 across 6 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 49.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $43.40 | 49.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.26 | 22.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.71 | 15.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.98 | 12.6% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $87.35 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $43.40 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.98 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
144 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 598 | 88 |
| Omeprazole | Omeprazole | 500 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 436 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 416 | 87 |
| Atorvastatin Calcium | Atorvastatin Calcium | 341 | 72 |
| Furosemide | Furosemide | 331 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 304 | 67 |
| Montelukast Sodium | Montelukast Sodium | 302 | 70 |
| Gabapentin | Gabapentin | 296 | 68 |
| Potassium Chloride | Potassium Chloride | 295 | 57 |
| Metformin Hcl | Metformin Hcl | 293 | 61 |
| Lisinopril | Lisinopril | 282 | 55 |
| Trazodone Hcl | Trazodone Hcl | 279 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 277 | 71 |
| Losartan Potassium | Losartan Potassium | 259 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 249 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 213 | 55 |
| Meloxicam | Meloxicam | 204 | 48 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 200 | 33 |
| Allopurinol | Allopurinol | 178 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 172 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 171 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 167 | 37 |
| Carvedilol | Carvedilol | 153 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 147 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 146 | 27 |
| Ozempic | Semaglutide | 144 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 142 | 116 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 141 | 36 |
| Mounjaro | Tirzepatide | 140 | 19 |
| Sertraline Hcl | Sertraline Hcl | 137 | 27 |
| Cimetidine | Cimetidine | 127 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 30 |
| Simvastatin | Simvastatin | 123 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 23 |
| Prednisone | Prednisone | 120 | 81 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 15 |
| Jardiance | Empagliflozin | 102 | 16 |
| Pregabalin | Pregabalin | 98 | 15 |
| Azithromycin | Azithromycin | 92 | 82 |
| Celecoxib | Celecoxib | 92 | 26 |
| Linzess | Linaclotide | 91 | 23 |
| Fluconazole | Fluconazole | 90 | 61 |
| Famotidine | Famotidine | 89 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 18 |
| Januvia | Sitagliptin Phosphate | 87 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | 16 |
| Tramadol Hcl | Tramadol Hcl | 84 | 18 |
| Ibuprofen | Ibuprofen | 81 | 24 |
| Glimepiride | Glimepiride | 80 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 80 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 74 | 21 |
| Xarelto | Rivaroxaban | 71 | 12 |
| Donepezil Hcl | Donepezil Hcl | 70 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 59 |
| Indapamide | Indapamide | 66 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 65 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 62 | suppressed |
| Levofloxacin | Levofloxacin | 62 | 52 |
| Mirtazapine | Mirtazapine | 62 | 11 |
| Eliquis | Apixaban | 61 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 20 |
| Glipizide | Glipizide | 58 | 13 |
| Febuxostat | Febuxostat | 57 | 11 |
| Aripiprazole | Aripiprazole | 56 | suppressed |
| Clonazepam | Clonazepam | 56 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 56 | 14 |
| Metformin Hcl Er | Metformin Hcl | 56 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 54 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 12 |
| Ondansetron Odt | Ondansetron | 50 | 25 |
| Buspirone Hcl | Buspirone Hcl | 49 | 17 |
| Memantine Hcl | Memantine Hcl | 49 | suppressed |
| Nystatin | Nystatin | 49 | 33 |
| Promethazine Hcl | Promethazine Hcl | 49 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 37 |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Spironolactone | Spironolactone | 45 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 11 |
| Sucralfate | Sucralfate | 41 | 20 |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Torsemide | Torsemide | 39 | suppressed |
| Primidone | Primidone | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Methocarbamol | Methocarbamol | 35 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Mupirocin | Mupirocin | 34 | 25 |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 11 |
| Rybelsus | Semaglutide | 33 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 23 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 21 |
| Baclofen | Baclofen | 28 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 20 | 16 |
| Droxia | Hydroxyurea | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 13 |
| Acyclovir | Acyclovir | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 15 |
| Dutasteride | Dutasteride | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Prolia | Denosumab | 14 | 12 |
| Victoza 3-Pak | Liraglutide | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| V-Go 30 | Sub-Q Insulin Device, 30 Unit | 12 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $87.35 · 6 records | Otsuka America Pharmaceutical, Inc. | EVENITY, REXULTI, VOQUEZNA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error